Lipocine Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
LPCN$1.59-7.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
For the Years Ended December 31, 2025 and 2024
| Stockholder’s Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Treasury Stock · Additional · Accumulated Other · Total | ||||||||
| Number of Shares | Amount | Number of Shares | Amount | Paid-In Capital | Comprehensive Gain | Accumulated Deficit | Stockholders’ Equity | |
| Balances at December 31, 2023 | 5,315,830 | $8,860 | 336 | $(40,712) | $220,171,250 | $7,259 | $(199,777,214) | $20,369,443 |
| Net income | - | - | - | - | - | - | 8,352 | 8,352 |
| Unrealized gain on marketable investment securities | - | - | - | - | - | 1,879 | - | 1,879 |
| Stock-based compensation | - | - | - | - | 408,551 | - | - | 408,551 |
| Common stock sold through ATM offering | 32,110 | 3 | - | - | 209,337 | - | - | 209,340 |
| Balances at December 31, 2024 | 5,347,940 | $8,863 | 336 | $(40,712) | $220,789,138 | $9,138 | $(199,768,862) | $20,997,565 |
| Stockholder’s Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Treasury Stock · Additional · Accumulated Other · Total | ||||||||
| Number of Shares | Amount | Number of Shares | Amount | Paid-In Capital | Comprehensive Gain (Loss) | Accumulated Deficit | Stockholders’ Equity | |
| Balances at December 31, 2024 | 5,347,940 | $8,863 | 336 | $(40,712) | $220,789,138 | $9,138 | $(199,768,862) | $20,997,565 |
| Net loss | - | - | - | - | - | - | (9,627,505) | (9,627,505) |
| Unrealized net loss on marketable investment securities | - | - | - | - | - | (4,693) | - | (4,693) |
| Stock-based compensation | - | - | - | - | 242,497 | - | - | 242,497 |
| Vesting of restricted stock units | 3,625 | - | - | - | - | - | - | - |
| Common stock sold through ATM offering | 806,878 | 81 | - | - | 2,869,471 | - | - | 2,869,552 |
| Balances at December 31, 2025 | 6,158,443 | $8,944 | 336 | $(40,712) | $223,901,106 | $4,445 | $(209,396,367) | $14,477,416 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.